Cardinal Health, Inc. vs Oracle Corporation: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Oracle Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Oracle Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Oracle Corporation is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $67.4B for Oracle Corporation, while their respective market capitalizations stand at $56.0B and $393.6B. Both Cardinal Health, Inc. and Oracle Corporation are headquartered in United States, so they compete in a shared home market and regulatory environment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Oracle Corporation: Oracle is best known for Oracle Database, the relational database behind many bank, airline, telecom and government systems. Over four decades it added middleware (BEA), applications (PeopleSoft, Siebel, Hyperion, NetSuite), Java and hardware (Sun Microsystems) and healthcare records (Cerner). The company moved its headquarters from Redwood Shores, California to Austin, Texas in December 2020. Since 2023 its identity has shifted again, toward Oracle Cloud Infrastructure as a landlord for AI model training.

Cardinal Health, Inc. and Oracle Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Oracle Corporation.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Oracle Corporation business model: Oracle sells to businesses and governments, not consumers. Its largest revenue line is cloud services and license support: customers pay recurring fees for OCI compute, storage, GPUs and database services, for Fusion Cloud ERP, HCM, SCM and NetSuite subscriptions, and for annual support on licensed Oracle Database and middleware. Smaller lines are new cloud and on-premise licenses (Q1 FY2027 software revenue was $5.5 billion, down 3% as customers migrate to cloud), services ($1.4 billion in Q1 FY2027) and hardware ($0.8 billion). OCI is now the growth engine: in Q1 FY2027 infrastructure revenue was $7.4 billion against $4.2 billion for cloud applications.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Oracle Corporation.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Oracle Corporation competitive advantage: Oracle's edge comes from its installed base. Oracle Database runs core financial, telecom and government systems, and moving those workloads is slow, expensive and risky, which keeps support revenue recurring. OCI adds a price-performance pitch built on bare-metal servers and RDMA networking for large GPU clusters, and Oracle can offer the same database inside rival clouds. Its weaknesses are a smaller cloud services catalog than AWS or Azure and a long record of customer complaints about licensing audits.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Oracle Corporation each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Oracle Corporation growth strategy: Oracle's growth plan rests on renting AI training and inference capacity at very large scale. It is building data centers for OpenAI under the Stargate program (a partnership OpenAI describes as over $300 billion across five years and up to 4.5 gigawatts), and it also serves xAI, Meta, NVIDIA and AMD workloads. In Q1 FY2027 it booked more than $30 billion of new AI cloud contracts, delivered 850 MW of additional capacity and over 300,000 GPUs. Alongside that, Oracle runs its database inside Azure, AWS and Google Cloud data centers (multicloud database), pushes Fusion and NetSuite SaaS, and is rebuilding Oracle Health, the former Cerner business it bought for $28.3 billion in 2022.

A closer look at the financial trajectory of Cardinal Health, Inc. and Oracle Corporation rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Oracle Corporation: Oracle's revenue grew from $39.1 billion in FY2020 to $57.4 billion in FY2025 and $67.36 billion in FY2026, when net income was $17.09 billion. Growth is now driven by cloud: Q1 FY2027 cloud revenue (IaaS plus SaaS) was $11.6 billion, up 62%, and operating cash flow was a record $23 billion for the quarter. The other side of the ledger is capex. FY2026 capital spending of $55.7 billion pushed free cash flow negative, and Oracle has funded the gap with bond issuance and equity sales. Management guides to at least $90 billion of FY2027 revenue and non-GAAP EPS of $8.10.